Browse Tag

coronavirus drug

NIH: Hydroxychloroquine does not benefit adults hospitalized with coronavirus

3 mins read

The FINANCIAL — A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. Though found not to cause harm, early findings in June when the trial was stopped indicated that the drug was not improving outcomes in COVID-19 patients. Final data and analyses of the trial, which was funded by the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, can be found online in the Journal of the American Medical Association.  The trial,…

Read More »

NIH: Hydroxychloroquine does not benefit adults hospitalized with coronavirus

Published on
3 mins read

The FINANCIAL — A National Institutes of Health clinical trial evaluating the safety and effectiveness of hydroxychloroquine for the treatment of adults with coronavirus disease 2019 (COVID-19) has formally concluded that the drug provides no clinical benefit to hospitalized patients. Though found not to cause harm, early findings in June when the trial was stopped…

You might be interested in

Synairgen shares rise over 450% as COVID-19 drug has huge potential

Published on
2 mins read

The FINANCIAL — Synairgen plc, the respiratory drug discovery and development company which originated from research at the University of Southampton, is pleased to announce positive results from its clinical trial of SNG001, its wholly-owned inhaled formulation of interferon beta, in hospitalised COVID-19 patients. Researchers have announced the results of an initial trial which found the odds…

You might be interested in